Navigation Links
Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
Date:10/15/2008

tements as a result of certain factors, including the risks and uncertainties related to the development of new products and their commercial acceptance, and other factors discussed in Volcano's filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2007 and in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. Undue reliance should not be placed on forward-looking statements, which speak only as of the time they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, changed assumptions or otherwise. Actual results or experience could differ materially from the forward-looking statements.


'/>"/>
SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Volcano Presentation at Thomas Weisel Conference to Be Webcast
2. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
3. Volcano Announces Acquisition of Novelis, Inc.
4. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
5. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
6. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
7. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
8. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
9. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
10. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
11. Volcano Announces Closing of CardioSpectra Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... , Feb. 26, 2015 On behalf of ... affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript,s trade secrets, and that it improperly hired one ... order denying motions for judgment notwithstanding the verdict, a ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... Switzerland, Aug. 21 Roche (SWX: ROG.VX; RO.S),a world-leading ... has extended its offer to acquire all of the,outstanding ... VMSI ),to 5:00 p.m., New York City time on ... to expire at 5:00 p.m., New York City,time, on ...
... and PRAGUE, Czech Republic, Aug. 21 ... organization, today,announced it has completed the acquisition ... (CRO) headquartered in Prague, Czech,Republic. This move ... and,expands its capacity to provide full service ...
... WOODLANDS, Texas, Aug. 21 ,Lexicon Pharmaceuticals, Inc. ... the structure-activity relationship (SAR) of a class ... compounds,under evaluation by the company as potential ... gastrointestinal disorders. LX1031 is currently,under evaluation in ...
Cached Biology Technology:Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Medpace Strengthens Presence in Central Europe 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25
... at Northwestern University Feinberg School of Medicine played ... approval of Abraxane (paclitaxel protein-bound particles for injectable ... cancer. "The approval means that women with metastatic ... toxicities associated with solvents and will no longer ...
... Hopkins Medical Institutions in Baltimore, Md., reports that whole-body ... identify new, unexpected malignant cancerous tumors in patients, according ... Society of Nuclear Medicine's Journal of Nuclear Medicine. , ... to have cancer," said SNM member Richard L. Wahl, ...
... and Drug Administration (FDA) was "the single greatest obstacle ... safety officer David Graham at an unprecedented roundtable of ... (PLoS) and the Government Accountability Project. , In comments ... Senate Finance Committee, Graham said that, "Nearly 60,000 people ...
Cached Biology News:Nanoparticle Breast Cancer Drug Approved by FDA 2PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment 2Medical whistleblowers speak out 2Medical whistleblowers speak out 3
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: